Berislav V. Zlokovic, MD, PhD
Dr. Zlokovic is the director of the Zilkha Neurogenetic Institute and Professor and Chair of the Department of Physiology & Biophysics at the Keck School of Medicine of USC, and a Professor of Biological Sciences at the Dornsife College of Letters, Arts and Sciences. Zlokovic has a life-long career in studying the role of cerebral blood vessels in the pathogenesis and treatment of neurologic disorders such as Alzheimer’s disease and related disorders and stroke. He has published more than 350 publications. Thomson Reuters listed Zlokovic as one of “The World’s Most Influential Scientific Minds” in 2014 for ranking in 1% of the most-cited authors in the field of neurosciences from 2002 to 2012. Zlokovic received his M.D./Ph.D. from the University of Belgrade and did post-doctoral training with Hugh Davson at King’s College London.
Discoveries of his research team have contributed to the development of clinical trials for Alzheimer’s disease (Phase 2 and 3 studies) based on clearance of amyloid-beta and blockade of its re-entry into the brain, and stroke based on APC treatment currently in phase 2 studies in stroke patients as a neuroprotectant. He received the MetLife Award for Medical Research, the Potamkin Prize from the American Academy of Neurology, the MERIT Award from NIA and the Javits Award from NINDS. He is a fellow of the AAAS, and a member of the Danna Alliance for Brain Initiative, and the European Academy of Sciences. Zlokovic was scientific co-founder of ZZ Biotech.
Thomas P. Davis, PhD
Dr. Davis is Professor of Medical Pharmacology, Physiology and Neurosciences and Director of the Blood Brain Barrier Laboratory at the University of Arizona College of Medicine.
Prior to his position in academia, Dr. Davis worked at Abbott Pharmaceuticals as a member of the team that researched, developed and marketed TDX for therapeutic drug monitoring. The focus of his research over the past 30 plus years is the blood brain barrier (BBB)/Neurovascular Unit in health and disease and specifically the effects of pain, inflammation and stroke on the BBB. He studies how tight junctions of the BBB form a uniquely regulated tight seal while remaining capable of rapid modulation and regulation in neuropathological disease states. Dr. Davis holds several honors including Membership in the Loyola Marymount University College of Science and Engineering Wall of Fame and Founders Day Awardee and speaker at the University of Arizona College of Medicine.
Dr. Davis has over 210 peer reviewed scientific publications, 30 invited book chapters, and holds awards from the National Institute on Neurological Disorders and Stroke, National Cancer Institute, National Institute of Mental Health and National Institute on Drug Abuse, where he has been continuously funded since 1981. Dr. Davis has also served as Chief Scientific Officer for Hansen Beverages Inc., a non-alcoholic beverage company,
John H. Griffin, PhD
Dr. Griffin is Professor of Molecular and Experimental Medicine at the Scripps Research Institute. He holds joint appointments in the Center for Integrative Molecular Biosciences and the Kellogg School of Science and Technology.
He serves on several editorial boards and is an honorary member of the American Society for Clinical Investigation. Dr. Griffin is a world expert on the activated Protein C system.
He is involved in long-term studies of plasma proteins that regulate thrombosis and hemostasis.
His biochemical, molecular biological and clinical research studies have contributed to define molecular mechanisms or defects that are related to development of thrombosis and ischemic stroke.
His work is also focused of protein engineering to establish structure-function relationships for clotting factors. Dr. Griffin has over 350 publications and holds several awards from the National Heart, Lung and Blood Institute.
Dr. Griffin received a BS in Physics from Santa Clara University and then a PhD in Biophysics from the University of California, Davis, in 1969. Following four years of postdoctoral training in spectroscopic studies of protein structure and function with Dr. Elkan R. Blout at Harvard Medical School and with Dr. Christian B. Anfinsen at the NIH in Bethesda, he continued NMR studies of peptide and protein structure at the French Atomic Energy Commission Laboratory (C.E.A.) in Saclay, France.
Howard Levy, MB BCh, PhD, MMM
Dr. Levy is the principal at Howard Levy Consulting LLC and currently serves full-time as Chief Medical Officer at Catalyst Biosciences.
Dr. Levy was the Senior Global Medical Program Director at CSL Bering in 2013, and he was the Senior Vice President and Chief Medical Officer at Inspiration Biopharmaceuticals, a company focused on innovation in hemophilia, in 2012. From 2008 to 2011, he served as Chief Medical Officer at Sangart, Inc., which was developing pegylated hemoglobin as an oxygen therapeutic agent and a treatment for sickle cell crisis. Prior to Sangart, from 2006 to 2008, Dr. Levy was Associate Vice President, Clinical Research, Medical and Regulatory Affairs, at Novo Nordisk and was responsible for a number of clinical research programs, including recombinant Factor VIIa (NovoSeven). Earlier in his career, Dr. Levy was Clinical Research Physician and Medical Director, Acute Care in the U.S. Medical Division of Eli Lilly and Company supporting post-marketing clinical trials and medical affairs for recombinant Activated Protein C (Xigris) in severe sepsis and antiplatelet agents ReoPro and prasugrel. He was also Chief of Critical Care Medicine at the University of New Mexico in Albuquerque for 11 years.
Dr. Levy has served on many clinical trial committees including Data Safety Monitoring Boards, Clinical Evaluation Committees and Health Economic assessment. He has more than 100 peer-reviewed publications and book chapters.
Dr. Levy received his Ph.D. and MB MCh from University of Witwatersrand, Johannesburg, South Africa and Masters of Medical Management at Carnegie-Mellon, Pittsburgh, PA.